导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.18% | 2449/4773 |
| 近一周 | -1.92% | 1935/5458 |
| 近一月 | -3.37% | 2029/5421 |
| 近一季 | -3.95% | 2178/5205 |
| 近半年 | -1.18% | 1739/4920 |
| 近一年 | 2.66% | 2247/4361 |
| 近两年 | 44.90% | 1696/2954 |
| 近三年 | 26.35% | 1235/2253 |
| 成立以来 | 42.51% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.46% 3221/4961 |
12.39% 2185/5312 |
- - |
- - |
| 2025 | 19.19% 2238/4813 |
-0.96% 2490/3635 |
2.09% 1879/4076 |
17.60% 2468/4524 |
0.24% 2107/4813 |
| 2024 | 14.90% 986/3463 |
2.77% 711/2808 |
-1.22% 988/3014 |
15.63% 1668/3129 |
-2.11% 1962/3463 |
| 2023 | -9.06% 1096/2656 |
4.22% 1016/2280 |
-3.82% 912/2385 |
-2.94% 797/2515 |
-6.54% 1818/2655 |
| 2022 | -18.35% 694/2207 |
-13.56% 783/1919 |
6.67% 640/2016 |
-13.40% 896/2113 |
2.25% 999/2208 |
| 2021 | -1.58% 810/1822 |
-1.59% 520/1255 |
3.15% 980/1330 |
-4.79% 737/1466 |
1.84% 781/1822 |
| 2020 | 29.36% 541/1250 |
-8.43% 609/1028 |
12.57% 680/1067 |
12.74% 368/1164 |
11.32% 550/1184 |
| 2019 | - - |
- - |
-1.90% 328/788 |
0.57% 507/850 |
7.02% 501/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 大成沪深300指数C VS. 长安沪深300非周期A(740101) |